ORGANIZING COMMITTEE

Amine Kamen
Department of Bioengineering
McGill University, 817 Sherbrooke St. W.
Macdonald Engineering Building, Room 387
Montreal, Canada
Tel.: +1(514)398 5775
mailtol: amine.kamen@mcgill.ca

Yvonne Genzel
Bioprocess Engineering Group, Team Upstream Processing
Max Planck Institute for Dynamics of Complex Technical Systems
Sandtorstr. 1, 39106 Magdeburg, Germany
Tel +49 391 6110 257
mailto: genzel@mpi-magdeburg.mpg.de

Francesc Gòdia
Departament d'Enginyeria Química, Biològica i Ambiental, Escola d'Enginyeria, Edifici Q, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain
Tel.: +34 93 581 4790
mailto: francesc.godia@uab.cat

FEE and APPLICATION

EUR 150.- Euros for academic participants and

EUR 250.- Euros for industry participants.

The fee covers course registration and ebook.

A **limited number of grants**, covering the course fee (not travel cost), are provided by ESACT. Applicants to the grants should indicate it in the course application, together with a motivation statement. Priority will be given to young PhD students from Academia**.**

All applications should be sent before 15th of July. Accepted applicants will be notified until August 5th and should confirm participation and complete payment by September 12th.

AIM

ESACT (European Society for Animal Cell Technology) offers an introductory intensive course in cell culture produced viral vaccines to meet the needs of the rapidly expanding research and development in Academia and Industry in the field. This course introduces the basic principles of vaccination and manufacturing of viral vaccines. Also, the course will provide an overview of the advanced strategies to respond to the challenges of new and established viral infection diseases. The course has been designed to benefit those starting their research activity in this field, both from Academia, Industry or Public Health Agencies. It is also of interest for those wishing to up-date their knowledge and know-how in cell production of viral vaccines.

COURSE OUTLINE

1. Principles of immunology and virology
2. Cell lines for vaccines production
3. Upstream process development and intensification
4. Analytical and potency assays
5. Downstream processing of viral vaccines
6. Vaccine formulation and delivery systems
7. Equipment, QbD and PAT
8. Regulatory issues
9. Vaccine markets and immunization policies
10. Several case studies for vaccine development and manufacturing, presented by international experts

Insights from WHO and Bill and Melinda Gates Foundation.

LECTURERS

Amine Kamen (McGill, Canada), Leo van der Pol (IntraVac, The Netherlands), Jorge Flores (PATH, USA), Yvonne Genzel (MPI, Germany), Francesc Gòdia (UAB, Spain), Isabelle Knott (GSK, Belgium), Cristina Peixoto (iBET, Portugal), Emma Petiot (CPE-Lyon Engineer School, France), Erin Sparrow (WHO, Switzerland) and Ray Prasad (Bill and Melinda Gates Foundation,USA).

Other information can be found at www.esact.org.

CELL CULTURE-BASED VIRAL VACCINES

SIXTH EDITION

September 27th – October 1st, 2021

Virtual Course



Photos: Ehl & MPI, Magdeburg

With the contribution of:

PROGRAM

6th ESACT CELL CULTURE-BASED VIRAL VACCINES COURSE

September 27th to October 1st, 2021

	Monday	Tuesday	Wednesday	Thursday	Friday
13.00 - 13.50	Introduction of course A. Kamen, McGill	Cells, upstream processing and process intensification Y. Genzel, MPI	Downstream processing of viral vaccines C. Peixoto, IBET	Formulation, adjuvants and delivery L. van der Pol, Intravacc	Clinical trials and vaccine development J. Flores, PATH
	Break				
14.00 - 14.50	Basic virology for antigen design A. Mullick, NRC	Polio vaccine and eradication strategy L. van der Pol, Intravacc	Potency assays and process analytical technologies E. Petiot	Influenza vaccines I. Legastelois, Sanofi	Vectored vaccines and one world-one health concept A. Kamen, McGill
	Break				
15.00 - 15.50	Basic immunology for vaccine design A. Mullick, NRC	WHO role and global responsibilities E. Sparrow, WHO	Virus like particles vaccines F. Godia, UAB	Use of insect cells: Cervarix I. Knott, GSK	Key role of Bill & Melinda Gates Foundation (BMGF) P. A. Gibert, BMGF
	Break				
16.00 - 16.40	Overview on COVID-19 candidate vaccines Y. Genzel	COVID-19 antigen design options and vaccination platforms Y. Genzel/All	COVID-19 vaccine manufacturing platforms and cost-effectiveness Y. Genzel/All	COVID-19 candidate vaccines immunology and protection Y. Genzel/All	Wrap-up session and course closing F. Godia/All

On-line (live) Course, all times in Central European Summer Time (CEST, UTC+2)

REGISTRATION

Deadline for application is June 15, 2021. The number of participants is limited. Selection will be made based on CV of applicants and motivation letter.

Online registration at www.esact.org/courses
Updated information available on www.esact.org

CONTACT

Contact for registration:

web: www.esact.org
ESACT Office – Birgit Marckhgott
E-mail: office@esact.org